Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.52 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RARA | P10276 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23566420 | 0.77 | DEGS1 (0.75) | HCAR3DEGS1RAB9AKMT2AKDM4E | |
| SCHEMBL2664555 | 0.75 | HCAR3 (0.55) | HCAR3DEGS1RAB9AKMT2AKDM4E | |
| SCHEMBL20641476 | 0.73 | RAB9A (0.66) | HCAR3DEGS1RAB9AKMT2AKDM4E | |
| SCHEMBL23437637 | 0.71 | DEGS1 (0.74) | HCAR3DEGS1RAB9AKMT2AKDM4E | |
| SCHEMBL4443620 | 0.70 | ALDH1A1 (0.57) | XDHSLC22A12 | |
| SCHEMBL29220747 | 0.70 | HCAR3 (0.71) | HCAR3DEGS1RAB9AKMT2AKDM4E | |
| SCHEMBL29519035 | 0.70 | DEGS1 (0.82) | HCAR3DEGS1RAB9AKMT2AKDM4E | |
| SCHEMBL4909745 | 0.70 | ALDH1A1 (0.53) | KMT2AKDM4ERARAXDHSLC22A12 | |
| SCHEMBL13870148 | 0.70 | DEGS1 (0.82) | HCAR3DEGS1RAB9AKMT2AKDM4E | |
| SCHEMBL2664544 | 0.70 | HCAR3 (1.00) | HCAR3DEGS1RAB9AKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| EP-1568367-B3 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-7390908-B2 | Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes | ASTRAZENECA AB (SE) | 2008-06-24 | — | — | US | disclosed |
| EP-1568367-B1 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| EP-1568367-A1 | Compounds effecting glucokinase | AstraZeneca AB (SE) | 2005-08-31 | — | — | EP | disclosed |
| EP-1529530-A1 | Compounds affecting glucokinase | AstraZeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207636-A1 | Compounds Effecting Glucokinase | GCKR, GCK, SLC5A2 | HCAR3 1545/4885DEGS1 951/4885RAB9A 3175/4885 |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | GCKR, GCK, SLC5A2 | HCAR3 1545/4885DEGS1 951/4885RAB9A 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.